Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
Thomas Powles, Srikala S. Sridhar, Yohann Loriot, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2200-2211
Closed Access | Times Cited: 95

Showing 1-25 of 95 citing articles:

The cancer-immunity cycle: Indication, genotype, and immunotype
Ira Mellman, Daniel S. Chen, Thomas Powles, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2188-2205
Open Access | Times Cited: 345
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
Bernadett Szabados, Mark Kockx, Zoe J. Assaf, et al.
European Urology (2022) Vol. 82, Iss. 2, pp. 212-222
Open Access | Times Cited: 116
Checkpoint Inhibitors in Urothelial Carcinoma—Future Directions and Biomarker Selection
Joshua J. Meeks, Peter C. Black, Matthew D. Galsky, et al.
European Urology (2023) Vol. 84, Iss. 5, pp. 473-483
Open Access | Times Cited: 35
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy
Noy Cohen Saban, Adam Yalin, Tomer Landsberger, et al.
Science Immunology (2023) Vol. 8, Iss. 81
Closed Access | Times Cited: 27
Fcγ receptors and immunomodulatory antibodies in cancer
Felipe Gálvez‐Cancino, Alexander P. Simpson, Cristóbal Costoya, et al.
Nature reviews. Cancer (2023) Vol. 24, Iss. 1, pp. 51-71
Closed Access | Times Cited: 27
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
Scott A. Tomlins, Nickolay A. Khazanov, Benjamin J. Bulen, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 25
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience
Brendan J. Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 22, pp. 4586-4595
Closed Access | Times Cited: 24
Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures
Ying Dong, Xiaoqing Wu, Chaojie Xu, et al.
Aging (2024)
Open Access | Times Cited: 14
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial
Scott Kopetz, Danielle Murphy, Jie Pu, et al.
Nature Medicine (2024)
Open Access | Times Cited: 11
Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts
Lilian Marie Boll, Sergio Vázquez Montes de, Marta E. Camarena, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
Pauline Parent, Gautier Marcq, Sola Adeleke, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 18
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis
Alberto Martini, Daniele Raggi, Giuseppe Fallara, et al.
Cancer Treatment Reviews (2022) Vol. 104, pp. 102360-102360
Closed Access | Times Cited: 27
p53 mutation and deletion contribute to tumor immune evasion
Si‐Yang Maggie Liu, Tianyao Liu, Jiaxuan Jiang, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 15
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience
Dimitra Rafailia Bakaloudi, Rafee Talukder, Genevieve Ihsiu Lin, et al.
Clinical Genitourinary Cancer (2023) Vol. 21, Iss. 5, pp. 584-593
Open Access | Times Cited: 15
Transforming growth factor‐β signalling in tumour resistance to the anti‐PD‐(L)1 therapy: Updated
Keywan Mortezaee, Jamal Majidpoor
Journal of Cellular and Molecular Medicine (2023) Vol. 27, Iss. 3, pp. 311-321
Open Access | Times Cited: 14
FGFR Inhibition in Urothelial Carcinoma
Roger Li, Joshua Linscott, James W.F. Catto, et al.
European Urology (2024)
Closed Access | Times Cited: 5
Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study
Tetsuya Shindo, Kohei Hashimoto, Toshiki Kenuka, et al.
Journal of Geriatric Oncology (2025) Vol. 16, Iss. 2, pp. 102183-102183
Closed Access
Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis
Weiming Liang, Zhijin Wang, Zhilong Huang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day
Brigida Anna Maiorano, Ugo De Giorgi, Davide Ciardiello, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 411-411
Open Access | Times Cited: 20
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes
Andrea Palicelli, Stefania Croci, Alessandra Bisagni, et al.
Biomedicines (2022) Vol. 10, Iss. 2, pp. 236-236
Open Access | Times Cited: 20
Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management
Joaquim Bellmunt, Begoña P. Valderrama, Javier Puente, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 174, pp. 103683-103683
Open Access | Times Cited: 19
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
Petros Grivas, Enrique Grande, Ian D. Davis, et al.
ESMO Open (2023) Vol. 8, Iss. 6, pp. 102050-102050
Open Access | Times Cited: 11
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study
Makito Miyake, Takuto Shimizu, Yuki Oda, et al.
Japanese Journal of Clinical Oncology (2022) Vol. 53, Iss. 3, pp. 253-262
Closed Access | Times Cited: 16
Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer
Xiaohe Su, Kaifeng Jin, Qiji Guo, et al.
British Journal of Cancer (2024) Vol. 130, Iss. 5, pp. 852-860
Open Access | Times Cited: 3
Identification of a cisplatin resistant-based prognostic immune related gene signature in MIBC
Yunfei Wu, Zhijie Xu, Guanghou Fu, et al.
Translational Oncology (2024) Vol. 44, pp. 101942-101942
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top